Genomind Is Excited to Appoint Rina Wolf to Its Board of Directors

KING OF PRUSSIA, PA--(Marketwired - May 18, 2015) - Genomind, a pharmacogenetic testing laboratory specializing in personalized medicine in the field of psychiatry, today announced that it has appointed Rina Wolf, Vice President of Commercialization Strategies, Consulting & Industry Affairs for XIFIN, Inc., a leading financial and health economics optimization company, to its Board of Directors.

Michael Koffler, Genomind's President and CEO stated, "We are delighted that Rina has joined our Board. Her significant experience and knowledge of the reimbursement, regulatory and commercialization challenges and opportunities faced by molecular diagnostic laboratories will be extremely valuable to Genomind as we continue our rapid growth. Our Genecept™ Assay has been shown in multiple studies to significantly improve clinical care and reduce overall costs for psychiatric patients, and we look forward to Rina's contributions as we engage with the private and public payer communities."

Wolf is a nationally recognized expert in the field of laboratory commercialization and reimbursement, with over 20 years of experience in the diagnostic laboratory industry specializing in molecular diagnostic laboratories. Prior to joining XIFIN, Wolf held executive positions in the areas of commercialization and reimbursement at Genomic Health, Inc., RedPath Integrated Pathology, Inc., and Esoterix (now LabCorp), where she was responsible for creating and implementing successful reimbursement strategies.

"Precision medicine and genomics hold the promise to significantly enhance patient care," noted Wolf. "Genomind is uniquely positioned to strengthen its lead in this emerging market through its dedication to developing personalized therapies for psychiatric treatments and mental health conditions. I look forward to working with their Board and management team to help deliver on their compelling mission."

Wolf has provided consulting expertise to more than 50 laboratories in the areas of commercialization, fiscal optimization and compliance. She lectures extensively within the industry and is an active participant and advocate in industry affairs. She is a member of relevant American Medical Association workgroups, a former president and board member of the California Clinical Laboratory Association, and is an active participant with the American Clinical Laboratory Association, AMA and the Personalized Medicine Coalition. She holds a Bachelor of Arts degree from UCLA and a Master's degree in healthcare administration.

About Genomind

Genomind is a pharmacogenetic testing laboratory specializing in personalized medicine in the field of psychiatry, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients' lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research. Learn more at

About the Genecept™ Assay

The Genecept Assay is a comprehensive, simple-to-use tool for understanding genetic and biological markers that best inform response to different psychiatric treatments. The Assay is Genomind's core product and utilizes a proprietary panel of biomarker tests, providing an analytic report, and a psychopharmacologist consultation. The Assay can be used for a range of psychiatric conditions including depression, anxiety disorders, bipolar disorder, PTSD, and schizophrenia. For more information on the Assay, including information about the specific genes in the panel, please visit






Media Relations

To speak with XIFIN directly, contact Fran DuCharme at 858.436.2939 or complete the form below for assistance.

To speak with our PR firm, contact Amy Thompson at 202.297.3462.